SEC Form SC 13G filed by Reneo Pharmaceuticals Inc.

2/5/24 4:01:21 PM ET

$RPHM

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RPHM alert in real time by email

SC 13G 1 j15240sc13g.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

RENEO PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, $0.0001 Par Value

(Title of Class of Securities)

	75974E103
	(CUSIP Number)

12/31/2023
(Date of Event Which Requires Filing of This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

	x	Rule 13d-1(b)

	¨	Rule 13d-1(c)

	¨	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 75974E103
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) OCTAGON CAPITAL ADVISORS LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a)¨ (b)¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware

NUMBER OF

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

2,250,000

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

2,250,000

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,250,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.75%
12	TYPE OF REPORTING PERSON (see instructions) IA, PN

CUSIP No. 75974E103
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) OCTAGON INVESTMENTS MASTER FUND LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a)¨ (b)¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION CAYMAN ISLANDS

NUMBER OF

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

2,250,000

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

2,250,000

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,250,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.75%
12	TYPE OF REPORTING PERSON (see instructions) OO, PN

CUSIP No. 75974E103
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) TING JIA
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)	(a)¨ (b)¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION New York

NUMBER OF

BENEFICIALLY

OWNED BY

EACH REPORTING

PERSON WITH:

SOLE VOTING POWER

SHARED VOTING POWER

2,250,000

SOLE DISPOSITIVE POWER

SHARED DISPOSITIVE POWER

2,250,000

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,250,000
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.75%
12	TYPE OF REPORTING PERSON (see instructions) IN, HC

Item 1(a).	Name of Issuer:

	RENEO PHARMACEUTICALS, INC.

Item 1(b).	Address of Issuer’s Principal Executive Offices:

	18575 Jamboree Road, Suite 275-S Irvine, CA 92612

Item 2(a).	Name of Person Filing:

	This statement is being jointly filed by: • Octagon Capital Advisors LP, a Delaware limited partnership, (“Octagon”) • Octagon Investments Master Fund LP, an exempted limited partnership established in the Cayman Islands ("Master Fund") • Ting Jia, as the principal beneficial owner of Octagon (“Mr. Jia”). Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.” Octagon serves as the investment manager of the Master Fund. Mr. Jia is the managing member of Octagon. By virtue of these relationships, each of Octagon and Mr. Jia may be deemed to beneficially own the Issuer’s Common Shares directly owned by the Master Fund.

Item 2(b).	Address of Principal Business Office or, if none, Residence:

	645 Madison Avenue 21^st Floor, New York, NY 10065

Item 2(c).	Citizenship:

	USA

Item 2(d).	Title of Class of Securities:

	Common Stock, $0.0001 Par Value (“Common Shares” or “Shares”)

Item 2(e).	CUSIP Number: 75974E103

Item 3.	If this Statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	(a)	¨	Broker or dealer registered under Section 15 of the Act;
	(b)	¨	Bank as defined in Section 3(a)(6) of the Act;
	(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act;
	(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940;
	(e)	x	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
	(f)	¨	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
	(g)	x	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
	(h)	¨	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
	(i)	¨	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
	(j)	¨	A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
	(k)	¨	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Item 4.	Ownership.
	Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
	(a)	Amount Beneficially Owned:		2,250,000;
	(b)	Percent of Class: The percentage reported on this Schedule 13G, 6.75%, based on 33,311,787 shares of common stock outstanding as of November 9, 2023, as reported in the Form 10-Q filed by the issuer on November 13, 2023.		6.75%
	(c)	Number of shares as to which such person has:
		(i)	sole power to vote or to direct the vote:
		(ii)	shared power to vote or to direct the vote:	2,250,000
		(iii)	sole power to dispose or to direct the disposition of:
		(iv)	shared power to dispose or to direct the disposition of:	2,250,000

Item 5.	Ownership of Five Percent or Less of a Class.

	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Item 6.	Ownership of More than Five Percent on Behalf of Another Person.

	Octagon is the investment advisor to the Master Fund and other accounts. Mr. Jia is the control person of Octagon. The Master Fund holds the Stock for the benefit of its investors, and the Master Fund and Octagon, for the benefit of its investors have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

	Not applicable.

Item 8.	Identification and Classification of Members of the Group.

	Not applicable.

Item 9.	Notice of Dissolution of Group.

	Not applicable.

Item 10.	Certification.

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect for the time being.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

	02/5/2024
	Date

	/s/ Ting Jia
	Signature

	Ting Jia/ Managing Member
	Name/Title

Get the next $RPHM alert in real time by email

Recent Analyst Ratings for

$RPHM

Date	Price Target	Rating	Analyst
12/15/2023		Outperform → Market Perform	Leerink Partners
12/15/2023		Buy → Hold	Jefferies
12/15/2023	$30.00 → $1.50	Buy → Neutral	H.C. Wainwright
12/14/2023		Buy → Neutral	Ladenburg Thalmann
12/14/2023	$23.00 → $1.45	Buy → Underperform	BofA Securities
12/14/2023		Outperform → Mkt Perform	William Blair
12/14/2023	$28.00 → $3.00	Outperform → Neutral	Robert W. Baird
12/14/2023	$25.00 → $4.00	Overweight → Neutral	Piper Sandler

More analyst ratings

SEC Form SC 13G filed by Reneo Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for
$RPHM

$RPHM
Leadership Updates

Live Leadership Updates

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors

Reneo Pharmaceuticals Announces Changes to its Board of Directors

$RPHM
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by Reneo Pharmaceuticals Inc.